Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$17.0 - $25.43 $119,408 - $178,620
-7,024 Reduced 38.23%
11,348 $219,000
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $140,913 - $445,153
18,372 New
18,372 $384,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $600M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.